PharmAust (ASX:PAA) escalates dosage of third patient cohort in MND/ALS trial
PharmAust (ASX:PAA) has announced that all 12 patients in cohort three have received an initial escalated dose in its phase one/two trial of MPL in MND and ALS.
Be the first with the news that moves the market
Subscribe Be the first with the news that moves the market
PharmAust (PAA) announces that all 12 patients in ...
Read More
Other Stories in Business
- Gulf War veteran executed for 1998 quadruple murder despite claims of mental illness
- Guardant Health (GH) Reports Strong Q1 2025 Revenue Growth
- Connecting Asia's startup ecosystem
- Connecting Asia's startup ecosystem
- From a Joke That Went Too Far to Radical Ideology – How Did the Memecoin Paradigm Change
- From a Joke That Went Too Far to Radical Ideology – How Did the Memecoin Paradigm Change
- L3Harris Technologies Stock: A Steady Course In A Changing World (NYSE:LHX)
- L3Harris Technologies Stock: A Steady Course In A Changing World (NYSE:LHX)
- Business First Bancshares, Inc. (BFST) Q1 2025 Earnings Call Transcript
